By Michele Maatouk
Date: Friday 31 Oct 2025
(Sharecast News) - AIM-listed Genedrive said on Friday that shareholder David Nugent had shown "willingness" to make a cash injection into the point-of-care pharmacogenetic testing company.
The company said that since its general meeting on 15 October, it has "continued to engage constructively" with Nugent - who has a 16% interest in the group - about financing options.
Genedrive said Nugent "has recently indicated a willingness" to make a direct cash injection into the company by way of a loan of up to £1m on terms to be agreed between the parties.  
"Whilst there can be no certainty that this additional funding will be received the company welcomes this indication of potential additional financial support from David Nugent and further announcements will be made in due course," it said.
At 1010 GMT, the shares were up 10% at 0.94p.
Email this article to a friend
or share it with one of these popular networks:
			
			 
		
You are here: news